Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: EXEL

Exelixis, Inc.

Healthcare | Biotechnology

No licensed closing price on file for EXEL. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2026)$2.78

Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 12:41 UTC.

What Exelixis, Inc. does

Exelixis is an oncology company that develops cancer medicines, with four marketed pharmaceutical products currently generating the majority of revenues. The company's flagship molecule, cabozantinib, is approved in the United States and numerous other countries for treating various cancers including renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and neuroendocrine tumors, both as a monotherapy and in combination with other drugs. Beyond cabozantinib, Exelixis markets cobimetinib for melanoma and esaxerenone for hypertension in Japan through partnerships.

Summarized from Exelixis, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (FY2026)$2.78
Return on equity36.21%

Revenue, margins & earnings

FY2022 Net income: $182MFY2022 Taxes & interest: $19MFY2022 Operating costs: $1.41B$1.61BFY2022FY2023 Revenue: $1.83B — margin split not shown (non-operating gains)$1.83BFY2023FY2024 Net income: $521MFY2024 Taxes & interest: $83MFY2024 Operating costs: $1.56B$2.17BFY2024FY2025 Net income: $783MFY2025 Taxes & interest: $90MFY2025 Operating costs: $1.45B$2.32BFY2025FY2026 Net income: $783MFY2026 Taxes & interest: $90MFY2026 Operating costs: $1.45B$2.32BFY2026
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-12
  • 2026-08-12DirectorSale-9,812$526.5K
  • 2026-06-03DirectorSale-3,925$198.4K
  • 2026-06-03DirectorSale-9,812$492.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Exelixis, Inc. do?

Exelixis is an oncology company that develops cancer medicines, with four marketed pharmaceutical products currently generating the majority of revenues.

When did EXEL last file with the SEC?

Exelixis, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 12:41 UTC. This page is also available as JSON at /api/data?ticker=EXEL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for EXEL and 5,000+ tickers.

Create a free account — keep EXEL
For your agent
GET /api/data?ticker=EXEL

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt